Hyperfine Stock News

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine announces it has received CE Marking and UK Conformity Assessment (UKCA) approval for its Optive AI™ software.

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced their schedule for upcoming investor conferences. Hyperfine will discuss with investors recently announced milestones and growt...

Hyperfine, Inc. (NASDAQ:HYPR ) Q2 2025 Earnings Conference Call August 13, 2025 4:30 PM ET Company Participants Brett Hale - Chief Administrative Officer, CFO, Chief Compliance Officer, Treasurer & Corporate Secretary Maria Sainz - CEO, President & Director Conference Call Participants Brandon Carney - B. Riley Securities, Inc., Research Division Frank James Takkinen - Lake Street Capital Marke...

GUILFORD, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced second quarter 2025 financial results and provided a business update.

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine hits 100-patient milestone in portable MRI study, accelerating access to brain imaging in neurology clinics with next-gen Swoop® system.

GUILFORD, Conn.--(BUSINESS WIRE)--First patients enrolled in PRIME study at Yale School of Medicine, aiming to evaluate the potential of AI-powered portable MRI tech in the ED setting.

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that it will report financial results for the second quarter 2025 on Wednesday, August 13, 2025. Management will host a corresponding conference ca...

TORONTO--(BUSINESS WIRE)--Swoop® AI-powered portable MRI system shows 100% sensitivity for ARIA-E detection in Lecanemab patients (CARE PMR study data presented at AAIC 2025).